Welcome to our dedicated page for Entrada Therapeutics SEC filings (Ticker: TRDA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Entrada Therapeutics, Inc. (Nasdaq: TRDA) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Entrada is a clinical-stage biopharmaceutical company developing RNA- and protein-based therapeutics using its Endosomal Escape Vehicle (EEV™) technology for neuromuscular, ocular and other diseases.
For TRDA, key filings include periodic reports and current reports on Form 8-K. Recent Form 8-K filings furnished by Entrada cover quarterly financial results and corporate updates, such as results for the quarters ended June 30, 2025 and September 30, 2025. These filings confirm that Entrada’s common stock is registered on The Nasdaq Global Market under the symbol TRDA and identify the company as an emerging growth company.
Through this page, users can review how Entrada reports on its financial condition, collaboration revenue, research and development expenses, and other operating metrics in documents that are incorporated by reference into its SEC record. While the detailed content of annual reports on Form 10-K, quarterly reports on Form 10-Q and proxy statements is not reproduced here, this filings hub is the starting point for locating those documents on EDGAR.
Stock Titan enhances access to Entrada’s SEC filings by organizing them chronologically and highlighting document types that matter to investors, such as Forms 8-K, 10-K, 10-Q and, when applicable, insider transaction reports on Form 4. AI-driven tools can help summarize lengthy filings and clarify technical language, allowing readers to more quickly understand how Entrada describes its EEV platform, clinical programs and financial results in its official regulatory disclosures.
Entrada Therapeutics will hold its 2026 annual shareholder meeting virtually on June 10, 2026, for holders of its 38,820,616 outstanding common shares as of April 13, 2026. Stockholders will vote on electing two Class II directors, ratifying Ernst & Young as auditor for 2026, and approving amendments to the 2021 Stock Option and Incentive Plan and 2021 Employee Stock Purchase Plan.
The equity plan amendments would revise each plan’s 4%/1% annual “evergreen” formula so that outstanding pre-funded warrants, currently 3,367,003, are treated as outstanding shares when calculating future automatic share pool increases. The board argues this keeps equity capacity aligned with total capitalization and supports hiring and retention without shifting heavily toward cash compensation.
Entrada Therapeutics Chief Financial Officer Kory James Wentworth sold 2,500 shares of Common Stock in an open-market transaction. The sale occurred at a price of $12.95 per share. After the trade, he directly holds 119,010 shares. The transaction was executed under a Rule 10b5-1 trading plan adopted on March 6, 2025, indicating it was pre-scheduled.
TRDA issuer filed a Form 144 to sell 2,500 shares of Common Stock. The notice lists the securities as previously exercised stock options with a cash sale method dated 03/15/2024. The filing also reports recent Rule 10b5-1 sales by Kory Wentworth on 03/10/2026 (11,388 shares), 03/09/2026 (5,089 shares), 03/04/2026 (7,988 shares), 03/03/2026 (5,712 shares) and 03/02/2026 (2,939 shares).
Entrada Therapeutics President & COO Nathan J. Dowden reported open-market sales of a total of 15,010 shares of common stock. He sold 3,116 shares on March 9, 2026 at a weighted average price of $13.024 per share and 11,894 shares on March 10, 2026 at a weighted average price of $13.0476 per share. These transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on March 7, 2025. After the most recent sale, Dowden directly holds 198,588 shares of Entrada Therapeutics common stock.
Entrada Therapeutics, Inc. Chief Financial Officer Kory James Wentworth reported open-market sales of company common stock. He sold 5,089 shares on March 9, 2026 at a weighted average price of $13.0011 per share and 11,388 shares on March 10, 2026 at a weighted average price of $13.0151 per share. These transactions, totaling 16,477 shares, were executed pursuant to a Rule 10b5-1 trading plan adopted on March 6, 2025. After the most recent sale, he directly holds 121,510 shares of Entrada common stock.
Kory Wentworth reported planned sales of Common Stock under a 10b5-1 plan. The filing lists three trades: 03/02/2026 sale of 2,939 shares for $34,262.57, 03/03/2026 sale of 5,712 shares for $67,152.56, and 03/04/2026 sale of 7,988 shares for $97,892.14. The broker listed is Morgan Stanley Smith Barney LLC. The filing also records securities listed as previously exercised stock options (9,395 shares, 06/29/2023) and restricted stock units (7,082 shares, 09/01/2025).
Nathan Dowden reported two sales of Common stock: 7,223 shares on 03/02/2026 for $84,205.01 and 14,038 shares on 03/03/2026 for $165,036.34. The filing also lists 15,010 Restricted Stock Units dated 03/01/2024 and a securities line showing 38,284,313 (03/09/2026).
Entrada Therapeutics Chief Financial Officer Kory James Wentworth sold 7,988 shares of common stock in an open-market transaction. The sale occurred on March 4, 2026 at a weighted average price of $12.2549 per share, with individual trade prices ranging from $11.80 to $12.57.
The transaction was carried out under a pre-arranged Rule 10b5-1 trading plan adopted by the executive on March 6, 2025. Following this sale, Wentworth directly holds 137,987 shares of Entrada Therapeutics common stock.
Morgan Stanley Smith Barney LLC Executive Financial Services submitted a Form 144 relating to TRDA securities, showing 7,988 restricted stock units listed to be sold by the broker/issuer role on 03/01/2026. The filing also reports recent dispositions by Kory Wentworth of 5,712 and 2,939 common shares on 03/03/2026 and 03/02/2026, respectively, with reported proceeds of $67,152.56 and $34,262.57.